Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New compound ‘highly efficacious’ at reducing human tumour growth

06.07.2004


Treatment with a new dual cell cycle and angiogenesis pathway inhibitor blocks VEGF-induced vascular permeability, inhibits tumour angiogenesis and induces apoptosis in human tumour models said Dr Gerhard Siemeister of Schering AG, Corporate Research, Berlin speaking at the 18th meeting of the European Association of Cancer Research today (Tuesday 6 July, 2004).



Loss of cell cycle control (runaway growth) and tumour-induced angiogenesis (development of new blood vessels to supply the growing tumour with oxygen) are two major hallmarks of cancer. Loss of cell cycle control as a consequence of aberrant cyclin-dependent kinase (CDK) control has been directly linked to the molecular pathology of cancer. CDK’s are a family of enzymes required for the correct timing and order of events in the cell division cycle. Vascular endothelial growth factor (VEGF) / VEGF-receptor tyrosine kinase (VEGF-RTK) and platelet-derived growth factor (PDGF)-RTKs are two molecules known to be involved in tumour angiogenesis.

The new compound, called ‘ZK-CDK’, is a novel, chemically synthesized small molecule ATP-competitive kinase inhibitor that is unique in that combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule.


ZK-CDK was shown to inhibit a range of CDK’s as well as VEGF-RTK’s and PDGF-RTK’s resulting in an inhibition of the proliferation of human tumour cell lines in vivo. ZK-CDK blocked cell cycle progression in G1 and induced apoptosis, blocked VEGF-induced vascular permeability in vivo and reduced the blood supply of human tumour xenografts. “These animal data are very promising in terms of anti-tumour efficacy and tolerability”, said Dr Siemeister. “VEGF-RTK inhibitors have been shown to be well-tolerated by patients and we hope that ZK-CDK will be well tolerated. The CDK inhibiting mechanism of ZK-CDK, in contrast to cytotoxic chemotherapy, should arrest the proliferation of normal cells but not kill them, allowing them to recover during drug-free cycles”.

ZK-CDK was tested on mice as an oral preparation. The compound was tested against several tumour models including both solid tumours and haematological tumours. The compound showed efficacy in all models. However, ZK-CDK was particularly efficacious in slow-growing, hormone-independent, p53-negative models e.g. advanced, anti-hormone refractory breast and prostate tumours.

“This new compound is highly efficacious at inhibiting tumour growth and works by acting on two separate mechanisms that are involved in the development and perpetuation of human cancer cells”, said Dr Siemeister. The compound has already entered phase I clinical trials to determine tolerability and pharmacokinetics in humans and to establish its efficacy in humans”.

Bell Stuart | alfa
Further information:
http://www.fecs.be

More articles from Life Sciences:

nachricht During HIV infection, antibody can block B cells from fighting pathogens
14.08.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht First study on physical properties of giant cancer cells may inform new treatments
14.08.2018 | Brown University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

Im Focus: World record: Fastest 3-D tomographic images at BESSY II

The quality of materials often depends on the manufacturing process. In casting and welding, for example, the rate at which melts solidify and the resulting microstructure of the alloy is important. With metallic foams as well, it depends on exactly how the foaming process takes place. To understand these processes fully requires fast sensing capability. The fastest 3D tomographic images to date have now been achieved at the BESSY II X-ray source operated by the Helmholtz-Zentrum Berlin.

Dr. Francisco Garcia-Moreno and his team have designed a turntable that rotates ultra-stably about its axis at a constant rotational speed. This really depends...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

'Building up' stretchable electronics to be as multipurpose as your smartphone

14.08.2018 | Information Technology

During HIV infection, antibody can block B cells from fighting pathogens

14.08.2018 | Life Sciences

First study on physical properties of giant cancer cells may inform new treatments

14.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>